AbbVie Says Buying Spree Will Add R&D Heft Needed For Long-Term Growth

Cerevel Acquisition For $8.7bn Closely Follows $10.1bn ImmunoGen Buyout

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.